


Abstracts from the HTAi 2018 Annual Meeting
in Vancouver, Canada, June 1-5

International Journal of

Technology Assessment in Health Care

Conference Theme: Strengthening the
Evidence-to-Action Connection



International Journal of Technology Assessment in Health Care

Official Journal of Health Technology Assessment International

Editor-in-Chief

Wendy Babidge, PhD, BApp Sci (Hons), Grad Dip Bus, FIML, GAICD, PGCert HEHCP York

General Manager Research, Audit and Academic Surgery, Royal Australasian College of Surgeons

Adjunct Associate Professor, University of Adelaide

199 Ward St, North Adelaide South Australia 5006, Australia

Email: wendy.babidge@adam.com.au

Aims and Scope: The *International Journal of Technology Assessment in Health Care* has as its specific scope of interest the generation, evaluation, diffusion, and use of health care technology. It addresses the diverse audience of health care providers within medicine, public health, nursing, and the allied health professions; decision makers in government, industry, and health care organizations; and the scholarly disciplines such as ethics, economics, law, history, sociology, psychology, and engineering. The journal aims to fill the needs of those interested in the complexities of interaction between people and technology; technology as a force in social and organizational change; and technology as it is created, produced, applied, and paid for. It examines descriptively and analytically the effects of technology as perceived from the vantage point of different academic disciplines and policy-making organizations and examines methods necessary to conduct studies and evaluations of technology.

The focus of the journal is the international health care community. The experience of different countries in their encounter with health care technology, viewed comparatively, is invaluable to understanding its effects. Further, it is important to establish ties with the scholars, governments, and private institutions concerned with health care technology so that the experiences and learning of the international community in its parts can benefit the whole. The use of technology in health care has created some of the major dilemmas in society today. The journal serves as a forum for the wide range of professionals interested in the assessment of medical technology, its consequences for patients, and its impact on society.

Publishing, Advertising, and Subscription Offices: Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. (for U.S.A., Canada, and Mexico); or Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK (for U.K. and elsewhere).

2018 Subscription Information: *International Journal of Technology Assessment in Health Care* (ISSN 0266-4623) is

published bimonthly in February, April, June, August, October, and December by Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006; Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK. Annual institutional subscription rates for Volume 34 (2018): Institutions online only US \$593.00, and online only UK and elsewhere £341.00. Individuals online only US \$343.00, and online only UK and elsewhere £193.00. Single part: US \$114.00 in the U.S.A., Canada and Mexico; UK £65.00 and elsewhere. Online only for all institutions. Print editions ceased in 2014. Back volume prices are available upon request. *International Journal of Technology Assessment in Health Care* and other Cambridge journals can be found at <http://journals.cambridge.org>

© Cambridge University Press 2018

All rights reserved. No part of this publication may be reproduced, in any form or by any means, electronic or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: <http://www.cambridge.org/rights/permissions.permission.htm>

Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center, <http://www.copyright.com>, email: info@copyright.com.

Postmaster: Send address changes in the U.S.A. and Canada to: *International Journal of Technology Assessment in Health Care*, Journals Department, Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. Send address changes elsewhere to: *International Journal of Technology Assessment in Health Care*, Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK.

Founding Editors: Egon Jonsson and Stanley J. Reiser

Contents

Oral Presentations	1
OP02 Real-World Experience For Health Technology Assessment In Hospitals.....	1
OP03 Optimizing The Use Of RWE In HTA: Lessons From The ICER Summit.....	1
OP04 Cardiac Implant Registries: Systematic Review Of Global Practices.....	2
OP07 Real World Evidence: How Can It Improve Health Technology Assessment?.....	2
OP08 Using Real World Data To Support National Postmarketing Surveillance.....	3
OP09 Summary Of The 2018 Health Technology Assessment International Latin America Policy Forum Background Paper.....	4
OP10 Key Messages From The 2018 Health Technology Assessment Latin America Policy Forum.....	4
OP11 Findings From The 2017 Health Technology Assessment International Asia Policy Forum Survey.....	5
OP12 2017 Health Technology Assessment International Asia Policy Forum: The Importance Of Universal Health Care.....	5
OP13 2017 Health Technology Assessment International Asia Policy Forum: The Perspective Of Not-For-Profit Members.....	6
OP14 The 2017 Health Technology Assessment International Asia Policy Forum: The Perspective Of Industry Members.....	6
OP15 Actions Arising From The 2017 Health Technology Assessment International Asia Policy Forum.....	7
OP16 Decision Criteria That Influence Managed Entry Agreements.....	7
OP18 A Patient And Caregiver-Designed Framework For Managed Access Programs.....	8
OP19 Are Compassionate Use Programmes Good Predictors of Clinical Benefit?.....	8
OP20 When Are Nationally Available Discounts Introduced In NICE Appraisals.....	9
OP23 Setting The Value Of New Technologies - A Survey.....	9
OP24 Sensitizing Researchers And Developers For Patient Needs And Value.....	10
OP27 Patient Engagement At Scottish Medicines Consortium Committee Meetings.....	11
OP28 Partnership Working To Inform Patient Engagement In Health Technology Assessment.....	11
OP29 The Impact Of Individual Patient Input; Strengthening The Evidence.....	12
OP30 From Framework To Action: Implementing Patient Engagement.....	12
OP33 Adopting Health Technologies: NICE Approach For Evidence Into Action.....	13
OP35 Integrated Knowledge Translation In Policy Development.....	14
OP37 Health Technology Assessment Impact Assessment: Barriers And Enablers Perceived By Members Of The International Network Of Agencies For Health Technology Assessment (INAHTA).....	14
OP39 Evaluation Of Discharge Planning And Transitional Care For The Elderly.....	15
OP40 Effect Of Advanced Nursing Practice On Hospital Use For The Elderly.....	15
OP43 Robotic Or Conventional Gait Training Rehabilitation? A Health Technology Assessment Study.....	16
OP44 HTA Of 3D Videolaparoscopy: Follow-up 12 Months After Introduction.....	17
OP45 HTA Of A Pediatric Biplanar Low-Dose X-Ray Imaging System.....	17
OP46 Redefining Mental Health Services For Youth: Evidence To Action.....	18
OP48 A Contextual Model For Evaluating The Value Of Multi-Indication Drugs.....	18
OP49 An Alternative Cost-Effectiveness Model For Health Technology Delivery.....	19
OP53 Comparing Approaches To Univariate Sensitivity Analysis.....	20
OP56 Rehabilitation Of Memory In Brain Injury: A Cost-Utility Analysis.....	20
OP60 Optimising Risk-Based Screening: The Case Of Diabetic Eye Disease.....	21
.....

OP61 Net Value Of Treating Hepatitis C With Newly Available Direct-Acting Antivirals	21
OP62 Economic Evaluation Of A Provincial Back Care Pathway.....	22
OP64 Review Of Economic Evaluations Of Next-Generation Precision Oncology	23
OP65 Genomics: From Horizon Scanning To National Health Policy.....	23
OP66 Tumor Profiling Tests In Early Breast Cancer: A Systematic Review.....	24
OP68 Methods For The Economic Evaluation Of Precision Medicine	24
OP71 Evidence Grading Systems Used In Health Technology Assessment Practice	25
OP72 Added Value Of Using Individual Patient Data Meta-Analysis.....	26
OP73 Problems And Promises Of Health Technologies: The Merits Of Early Health Technology Assessment	26
OP75 Tailoring Review Methods: Scope, Timescale And Needs Of Commissioners.....	27
OP77 Conducting Rapid Assessments: Lessons From 25 Years Of Good Practice.....	27
OP78 Code Of Ethics: Missing Cord In The Evidence-To-Action Connection?.....	28
OP79 A Meta-Framework To Inform Health Inequalities In Systematic Reviews.....	28
OP80 Reconciling Ethical And Economic Notions Of 'Value' For HTA	29
OP82 Ethical Challenges Related To Engaging Patients And The Public In HTA.....	30
OP83 Thinking Explicitly About Ethical Issues In Health Technology Assessment: Lessons From The Canadian Agency For Drugs And Technologies In Health.....	30
OP86 Outpatient Initial Management Of New-Onset Diabetes In Children.....	31
OP87 Nitrous Oxide As Sedation Regimen In Children—How To Assess Safety?.....	31
OP88 Reduction Of Biologics In Rheumatoid Arthritis: A Systematic Review	32
OP90 Do Patients With Open Fractures Need Urgent Surgery?	33
OP91 Individual Participant Data Meta-Analysis Of Exercise Rehabilitation In Heart Failure	33
OP92 Non-Opioid Therapy For Pain Management – Health Technology Assessment In A Time Of Crisis	34
OP95 Are Patient-Reported Outcome Measures Meeting Today's Standards?.....	34
OP96 Standardizing Collection Of Patient-Reported Experience Measures To Drive Service Improvement In Wales.....	35
OP97 Digital Home Services: Overcoming Critical Barriers In Early Decision Making.....	36
OP99 Sustaining Mobile Health Interventions In Vietnam: The Challenges.....	36
OP100 Implementing Electronic Health Record In A Children's Hospital.....	37
OP101 Hospital-Based Health Technology Assessment At UW Medicine.....	37
OP102 Multiple Criteria Decision Analysis In The Field Of Hospital-Based Health Technology Assessment.....	38
OP104 Moving Forward Hospital-Based Health Technology Assessment: Public Procurement Of Innovation.....	38
OP105 Disinvestment Toolkit: Patients Involvement In Disinvestment Activities	39
OP107 The Stakeholder Involvement Strategy For Horizon Scanning In Korea	40
OP108 From Essential Medicines List To Health Technology Assessment, And From Reimbursement To Pricing Decision-Making.....	40
OP109 Comparison Of The Health System Establishment Periods In Eighty-Eight Countries	41
OP112 Stakeholder Views As Evidence For NICE's Public Involvement Review.....	42
OP113 Iramuteq Analysis Of Trastuzumab's Public Consultation In Brazil	42
OP114 The Public's Role In Understanding The Value Of Health Technologies.....	43
OP118 Women's Preferences And Perspectives On Cervical Cancer Screening.....	44
OP119 Appraising Qualitative Research For Qualitative Evidence Syntheses.....	44

OP120 Rapid Qualitative Reviews: A Scoping Review Of Guidance And Examples	45
OP121 Experiences With Using The GRADE-CERQual Approach In Systematic Review.....	45
OP122 Applications For Research Funding: How Many Peer Reviewers Do We Need?.....	46
OP123 Translating Evidence To Action – The Role Of Health Research Funders.....	47
OP124 Research Gaps In Health Technology Assessment In Brazil.....	47
OP125 Increasing Capacity For Utilization Of Health Technology Assessment.....	48
OP126 Shared Decision-Making Influences Patients’ Adoption Of Stents In China	48
OP128 Evaluating The NPS MedicineWise Medicines Information Phone Service	49
OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada	50
OP136 Full Texts Versus Conference Abstract Data: How Does The Message Change?.....	50
OP139 Not Using Data From ‘Failed’ Primary Research Undermines Health Technology Assessment Reporting.....	51
OP141 A Patient-Reported Outcome Measure For Hemorrhoidal Disease.....	51
OP143 Conceptualizing Patients’ Experience With Atrial Fibrillation	52
OP144 Health Economics In Clinical Practice Guidelines: The Know-Do Gap.....	53
OP145 The Release Of The Fourth Edition Canadian Agency For Drugs And Technologies In Health (CADTH) Economic Guidelines – A Year In Review	53
OP149 Survival Rates And Costs In Hepatocellular Carcinoma With Cirrhosis	54
OP150 Acquired Immune Deficiency Syndrome Benefit Package: A Financial Review.....	54
OP151 Weathering The Development To Adoption Storm: NICE Safe Harbors.....	55
OP152 Level Of Agreement In EUnetHTA Joint Action 3 Early Dialogues.....	55
OP154 Industry And Clinician Views Of Medtech Innovation Briefings	56
OP157 Quo Vadis Romanian Health Technology Assessment?.....	57
OP158 Overview Of Technology Assessment For Multiple Sclerosis In The Brazilian Public Health System	57
OP160 Enhancing Innovation Through HTA: Experience From South Australia.....	58
OP161 Relationship Between Appropriateness And Arthroplasty Recommendation	58
OP163 European Network For Health Technology Assessment Joint Action 3 Relative Effectiveness Pilots: Pharma Company Experience.....	59
OP164 Hospital Budget Impact Of High-Cost Drugs: The Case Of Nusinersen	60
OP166 How Responsive Is Industry To Value Based Procurement?	60
OP169 Usability Evaluation Of A Portable Dry-Electrode Electrocardiography Device In Vietnam.....	61
OP170 Regulatory And Health Technology Assessment Considerations In Alzheimer’s Disease.....	61
OP171 Does Parallel Regulatory-Health Technology Assessment Reviews Affect Time To Health Technology Assessment Decisions?	62
OP172 Do Expedited Regulatory Pathways Affect Time To Health Technology Assessment Decision?.....	63
OP173 Eligibility Criteria For “Accelerated Access” Approval: A Global Survey.....	63
OP174 Development Of A Formal Priority-Setting For The Philippine Government.....	64
OP175 A National Perspective On Criteria And Methods For Resource Allocation.....	64
OP177 Identification Of Technologies Of No Or Low Added Value.....	65
Poster Presentations	66
PP02 Cost Effectiveness Of Tamoxifen For Breast Cancer Treatment In Ghana	66

PP03 Evidence Synthesis In Spasticity In Children	66
PP04 Co-Constructing Recommendations With Patients And Health Professionals	67
PP05 Developing Equity In Remote Locations Through Telediagnosis	67
PP06 HER2 Evaluation By CISH And SISH In Breast Cancer: A Meta-Analysis	68
PP08 Health Technology Assessment Of Autologous Chondrocyte Implantation.....	69
PP11 Would A Highly Specialized Technology Be Approved In England Under The New NICE Guidance?.....	69
PP14 Development Of The European Network For Health Technology Assessment Standards Tool For Registries In Health Technology Assessment.....	70
PP15 Incorporating Participatory Design Approaches Into HTA.....	70
PP16 Turning The Tide on Antibiotic Use With Consumers And Health Professionals	71
PP17 Comprehensive Evaluation Of A Technology With Expanding Indications	72
PP18 An Access Evidence IT Solution Within A Pharmaceutical Company.....	72
PP19 Opioid Poisoning Deaths: A National Picture.....	73
PP20 Assessment Of The First Software Combined With Telemonitoring Support	73
PP21 Reassessment Of Cochlear Implantation For Children In Kazakhstan	74
PP22 How Do Health System Leaders Use Evidence To Inform Action?.....	74
PP25 Direct Costs Of Ischemic Heart Disease: Real World Data From Brazil	75
PP26 Facial Palsy Therapy: Can Novel 'Smart Spectacles' Help People Smile?.....	76
PP27 A Prototype Patient Advocate Decision Aid For Oncology HTA.....	76
PP29 Evaluating Supplementary Search Methods: Outcomes To Measure And Why.....	77
PP32 Protocol For Evaluation Of Pharmaceutical Assistance Governance.....	77
PP34 A Cost-Utility Analysis Of The Syncope: Pacing Or Recording Trial	78
PP35 The National Oral Health Policy In Brazil: A Review Of The Literature	79
PP36 Early Diagnosis And Treatment Of Psoriatic Arthritis.....	79
PP39 Health Technology Assessment And Aging: Moving Evidence To Action.....	80
PP40 HTA Evaluations Of Combination Drugs: Positive Reimbursement Solutions	80
PP41 Toward Rules For Stakeholders' Involvement In Regional Health Technology Assessment Units.....	81
PP43 MACBETH In Brazilian Hospital-Based HTA: Thrombosis Prophylaxis	82
PP44 Effectiveness Of Insulin Glargine Versus Detemir In Type 1 Diabetes	82
PP46 When Composite Measures Or Indices Fail: Data Processing Lessons	83
PP47 Defining The Needs And Preferences Of Patients With Dry Eye Disease.....	83
PP48 Caregiver Perceptions And Experiences Of Diagnostic Genome-Wide Sequencing.....	84
PP49 Assessing Values In National And Regional Governance Of E-Health.....	85
PP50 Microcosting With Time-Driven Activity-Based Costing Applied On Brazilian HTA System: ECMO Case Study.....	85
PP51 Updating Canadian Pharmaceutical Budget Impact Analysis Guidelines.....	86
PP53 New Medical Device Law: Germany's Experience With Refund Restrictions	86
PP54 Effectiveness And Costs Analysis Of Smartphone Apps In Health Care.....	87
PP55 HTA And High Cost Innovative Therapies - Focus On Cancer Drugs	88
PP57 Grading The Quality Of Evidences In HTA Process.....	88
PP58 Hasty HTA: Delivering Health Technology Assessments Under Severe Time Constraints	89
PP59 Evaluating Reimbursement Applications With Decision-Oriented Evidence	89

PP60 Producing Qualitative Syntheses In Health Technology Assessment: Challenges From The Canary Islands	90
PP62 A Guide To Report And Review Innovative Indices Or Composite Measures	90
PP63 Factors Influencing Drug Prices Among Philippine Public Hospitals.....	91
PP65 Coordinated Implementation And Evaluation Of Promising Stroke Therapy.....	91
PP66 Hospital Cleaning: Detergent Or Disinfectant-Detergent? A Rapid Review.....	92
PP67 Validity Of A Questionnaire Assessing Patient Medication Experiences.....	93
PP68 Urinary And Fecal Collection Devices: A Cornerstone For Autonomy	93
PP69 Prostatic Artery Embolisation For Benign Prostatic Hyperplasia.....	94
PP70 Health Technology Assessment Evaluations Of Combination Drugs: The Italian Case Study.....	95
PP71 Long-Term Evaluation Of Broad Mental Health Interventions: A Review.....	95
PP75 Genetic Testing For Bladder And Kidney Cancer: An Interactive Evidence Map.....	96
PP76 Providing Information About Rheumatoid Arthritis Guideline In Brazil.....	96
PP81 Engagement Of Healthcare Professionals In Health Technology Assessment With Negative Results	97
PP83 Early Assessment Of Proof-Of-Problem To Guide Health Innovation.....	97
PP86 Impact Of Health Technology Assessment On Drug Price Negotiations: Canada	98
PP88 Intravenous Medication Delivery System Cost-Effectiveness Analysis.....	99
PP89 Living Lab Concept: An Innovation Hub For Elderly Residential Care	99
PP90 The Value Of Multi-Criteria Decision Analysis Use On Health Technology Decision Making Process.....	100
PP93 HTA Role In CoreHEM, A Multi-Stakeholder Core Outcome Set Project.....	100
PP95 Engagement Of Local Policymakers In HTA With Positive Results	101
PP96 Which Data For Dual Mobility Cups In Hip Arthroplasty?	102
PP97 Delineating Key Components Of Community Paramedicine Programs.....	102
PP98 Efficacy Of The Multi-Attribute Utility Instruments To Reflect Quality Of Life Of Cancer Patients.....	103
PP100 Rapid Evidence Assessment In Hospital Health Technology Assessment.....	103
PP102 Developing A Contextually-Informed Deprescribing Intervention.....	104
PP103 Early Decision Support In Innovative Procurement.....	105
PP105 Applying Horizon Scanning To Decision Making: The Case Of Tafamidis.....	105
PP108 Novel Approaches For Fair And Reasonable Value-Based Recommendations.....	106
PP109 Use Of Speech Recognition In Medical Reports: A Systematic Review.....	107
PP110 The Prophylactic Removal Of Impacted Third Molars: A Systematic Review.....	107
PP111 Toward Healthy Coagulation In Hemophilia	108
PP113 Towards a Systemic Approach of Value Judgment in HTA	108
PP114 Clinical Effectiveness Of Insulin Glargine; Findings And Implications	109
PP115 A Mobile Health App To Improve Knee Osteoarthritis Self-Management.....	109
PP116 Health Utilities And Neglected Conditions: A Chagas Disease Study.....	110
PP118 Cardiac Safety Of Trastuzumab For Metastatic Breast Cancer	111
PP119 How Much Evidence Is Enough For Action – ‘Adaptive Approach’ Helps?	111
PP121 Relationship Of Self-Reported Sleep Quality To Disease Status In Japan.....	112
PP122 A Quick Cost-Effectiveness Analysis Of Patent Foramen Ovale Closure In Korean Patients With Cryptogenic Stroke.....	112
PP123 Triangulate, Converge, Assess, And Recommend (TCAR): Evaluation Method.....	113

PP124 Health Technology Assessment And Feedback For Healthy Workplace Culture In Malaria Care In Low And Middle Income Countries.....	114
PP125 Patient-Focused Review Of Human Immunodeficiency Virus Benefit Package	114
PP126 Alfa-Alglucosidase For Pompe Disease: Literature Review.....	115
PP127 Issues On The Estimation Of The Opportunity Cost Threshold Value	115
PP128 Relationship Between Hemoglobin A1c And Medical Costs	116
PP129 The Need For Building Pharmacists HTA Capacity; The Nigerian Scenario	116
PP130 Economic Burden Of Nine Human Papillomavirus Strains (HPV9)-Related Diseases: A Real World Cost Analysis From Italy.....	117
PP131 Eliciting Implicit Value-Judgments In The HTA Process.....	118
PP134 The Impact Of Pan-Canadian Oncology Drug Review Coming Under The Remit Of The Canadian Agency For Drugs And Technologies In Health – Three Year Update	118
PP135 Cost-Effectiveness Of Cryoballoon Ablation In China: Real-World Results	119
PP136 Smartphone Intervention To Promote Healthy Lifestyles Among Teenagers	119
PP137 Colorectal Cancer Screening In The Philippines: Cost-Utility Analysis.....	120
PP138 Cost-Effectiveness Analysis Of Influenza A (H1N1) Chemoprophylaxis.....	120
PP140 Cancer And The Burden For Social Security System. Is It Sustainable?	121
PP142 Is Insulin Therapy Important For The Quality Of Life Of Diabetics?	122
PP145 Using Health Technology Assessment To Drive Guideline Development.....	122
PP146 Cost-Effectiveness Of Nivolumab Plus Ipilimumab In Advanced Melanoma	123
PP147 Olaratumab With Doxorubicin For Advanced Soft Tissue Sarcoma	123
PP148 Your Money Or Your Life? Are Price Negotiations Health Technology Assessment Best Practice?.....	124
PP149 Features Of Accountable And Reasonable Processes For Coverage Decision-Making	125
PP151 Comparison Of Patients Undergoing New Technology For Prostate Cancer	125
PP152 Options To Approach Health Litigation In Brazil: A Policy Brief.....	126
PP155 Telemedicine Enhance Universal Coverage Of Diagnostic Services.....	127
PP156 Risk Assessment Of Equipment Used In Intensive Care Units.....	127
PP158 The Art Of Collaboration In Guideline Development.....	128
PP159 Making Health Technology Assessment A Common Language In Controversies: A Hidden Role For The National Evidence-Based Healthcare Collaborating Agency	128
PP162 Bridging Brazil's Know-Do Gap On Social Engagement In Health Technology Assessment.....	129
PP163 The Cost-Reimbursement Mismatch For Heart Transplant In Brazil.....	130
PP164 Identifying Complications Of Partial Nephrectomy Using Physician Claims	130
PP165 The Resurrection Of The Cost-Minimization Approach In England	131
PP166 RedETS: 10 Years Of Economic HTA (Medical Devices) In Spain, 2006–2016	131

Poster Display Presentations..... 133

PD01 IPC For Prevention Of VTE: An Economic Analysis.....	133
PD04 Cost-Utility Of Quetiapine For Schizophrenia: A Systematic Review.....	133
PD05 Influence Of Economic Data In The Incorporation Of Medicines In Brazil	134
PD12 Economic Benefit Of Workplace Health Promotion: What Has Been Proven?	134
PD16 Riociguat In Pulmonary Arterial Hypertension: A Systematic Review.....	135

.....

PD18 Cost-Effectiveness Of Extracorporeal Life Support In Cardiogenic Shock.....	136
PD20 'Where's Waldo?' Incorporating Patient Aspects Into Rapid Reviews.....	136
PD22 Behavioral Factors Mediating Between Socioeconomic Status And Obesity.....	137
PD24 Data Collection By Patient Groups To Provide Patient Input	137
PD25 Principal Component Approximation: Medical Expenditure Panel Survey	138
PD26 Principal Component Approximation: Canadian Health Measures Survey	138
PD27 A Case Study Of Equity In Health From Zhejiang Province, China	139
PD30 Cost-Effectiveness Of Stereo-Electroencephalography For Refractory Epilepsy.....	139
PD31 Financial Impact Of Target Molecular Therapies In A Brazilian Hospital.....	140
PD33 Incorporation Of New Medicines In Brazil: A Descriptive Analysis.....	141
PD34 São Paulo Congenital Heart Corrections: Three-Years' Assist Registry.....	141
PD36 Scoping Of Interventions Of The Philippines' Most Burdensome Diseases.....	142
PD41 Use Of High-Sensitivity Cardiac Troponin Assays In Real-Practice Within Emergency Departments.....	143
PD42 Safety And Cost-Effectiveness Of Platelet-Rich Plasma For Chronic Wounds.....	143
PD43 Value-Based Procedure For Updating The Italian Health Benefit Package	144
PD44 Multi-Comparator Incremental Cost-Effectiveness Ratio: A New Framework For Cost-Effectiveness Analysis.....	144
PD47 Implanted Hypoglossal Nerve Stimulation For Obstructive Sleep Apnea	145
PD48 OTL38, A Tumour-Specific Agent In Surgery For Ovarian Cancer	146
PD49 Social Preferences In HTA: A Pilot Analysis In CLN2 Disease	146
PD50 Helping Innovators Navigate Policy And Regulatory Processes.....	147
PD53 Efficacy And Safety Of Nicotinamide In Hemodialysis Patients.....	147
PD54 Associated Factors Renal Graft Loss Using Real-World Evidence In Brazil	148
PD55 Diagnostic Accuracy Of Line Probe Assay Technique Compared To Sensitivity Test.....	149
PD56 Economic Evaluation Of Dalbavancin In European Countries.....	149
PD58 Cost-Effectiveness Of Quinolone For Acute External Otitis In Brazil	150
PD59 Formulation and Disclosure Of Information On Technologies In Health.....	150
PD60 Public Consultations And Their Influence On Health Decisions.....	151
PD61 HTA Regional Network In The Central Region Of Brazil: Survey In 2016	152
PD62 Off-Label Use Of Medicines For Public Health Needs	152
PD64 Diagnostic Accuracy Of The Nitrate Reductase Assay Technique	153
PD65 The Acquisition Of Eculizumab By Judicial Proceeding In Brazil	153
PD66 Indirect Comparison Of Treatments For Metastatic Melanoma.....	154
PD67 Strengthening And Accelerating Health Technology Assessments Through Artificial Intelligence.....	154
PD70 Cost-Effectiveness Of Deep Brain Stimulation For Epilepsy In Australia	155
PD76 The Value Of Continuous Lateral Rotation Therapy In The ICU.....	156
PD78 Minimally Invasive Capsulorhexis In Children's Cataracts.....	156
PD79 Poor Design And Reporting Impacts The Value Of Systematic Reviews.....	157
PD84 Hostile Anatomic Neck Of Abdominal Aortic Aneurysm Patients And EndoAnchor Cost Analysis	157
PD85 Testing Search Filters To Retrieve Economic Evaluations In Embase	158

Vignette Presentations **159**

VP01 A Disinvestment Toolkit: The Prioritization Of Technologies Of No Or Low Added Value..... 159

VP02 Real-World Evidence (RWE) And CADTH Pan-Canadian Oncology Drug Review 159

VP06 The Effectiveness And Ethics Of Prenatal Testing For Cystic Fibrosis..... 160

VP08 Description Of A Strategy To Face Judicialization Of The Right To Heal 160

VP09 Trastuzumab For Metastatic Breast Cancer Access Assessment In Brazil..... 161

VP10 Impact Of Health Technology Assessment On Policy And Clinical Decision Making In Korea..... 162

VP17 Hepatitis C Virus Treatment: A Meta-Analysis Of Long-Term Efficacy 162

VP18 Antibiotics And Orthopedic Surgery Without Implant: A Meta-Analysis 163

VP21 Factors Associated With Recommendations On Drugs For Rare Diseases 164

VP22 Future Trends For Managed Access Agreements In The UK..... 164

VP23 The New Cancer Drugs Fund: The Future Model Of Oncology Reimbursement..... 165

VP24 HTA To Assess Esthetic Procedures In France: Haute Autorité de Santé (HAS) Seven Year Experience 165

VP26 A Critical Appraisal Tool For Systematic Mixed Studies Reviews 166

VP30 The Use Of Artificial Intelligence In Health Technology Assessment 167

VP33 Peroral Endoscopic Myotomy For Treating Achalasia: A Rapid Review 167

VP34 Incorporation Of Medical Equipment In Northeastern Brazil 168

VP36 Benefit Cost Analysis Of Electronic Claims Processing System In Ghana..... 168

VP40 Robotic Surgery: From Health Technology Assessment To State Health Policy 169